FindTrial
Sign In

Study of Blood-Related Toxicity and outcomes arising from Treatment in Cervical Cancer Patients Receiving Extended-Field Radiation Therapy

Acute Hematological Toxicity and Treatment Outcomes in Patients treated with Extended Field Intensity Modulated Radiation Therapy for Cervical Cancer - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/07/113396
Enrollment
65
Registered
2026-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified Health Condition 2: C52- Malignant neoplasm of vagina

Interventions

Intervention1: Nil: Nil

Sponsors

Tata memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Histologically proven locally advanced cervical cancer with para-aortic nodal involvement (radiological or biopsy proven) Treated using intensity modulated radiotherapy with simultaneous or sequential nodal boost Patients who received NACT followed by (CT)RT or definitive (CT)RT

Exclusion criteria

Exclusion criteria: Patient treated with palliative intent Patients who received post operative/ salvage RT Patients who underwent re-irradiation

Design outcomes

Primary

MeasureTime frame
To determine the incidence of Grade 3/4 hematological toxicities and treatment interruptions in patients receiving EFRT for locally advanced cervical cancer as per common terminology criteria for adverse events (CTCAE) version 5Timepoint: 24 months—

Secondary

MeasureTime frame
To study the temporal profile in evolution of acute hematological toxicityTimepoint: 24 months;To report acute gastrointestinal (GI) and genito-urinary (GU) toxicityTimepoint: 24 months;To report local and nodal control, 2-year disease-free and overall survivalTimepoint: 24 months;To evaluate the patterns of failureTimepoint: 24 months;To report late GI, GU and vaginal toxicity as per CTCAE v. 5 Timepoint: 24 months—

Countries

India

Contacts

Public ContactDr Ankita Gupta

Tata Memorial Centre

ankita19.gupta.ag@gmail.com9592750011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026